AMERICAN STORES TO OPEN 20 DRUGSTORES, 14 FOOD/DRUG
AMERICAN STORES TO OPEN 20 DRUGSTORES, 14 FOOD/DRUG combo stores in 1986, the company declared in its just released annual report for 1985. "We intend to increase capital expenditures to the $280 mil. level in 1986 from $203 mil. last year, reflecting the acceleration of our new store development program," the chain added. Together with the four planned expanded food store openings, American Stores will open a total of 38 new stores in 1986. In 1985, the company opened five Jewel-Osco combo stores, nine Osco Drug Centers and nine Skaggs Alpha Beta combo stores, but closed 17 older stores for a net gain of six stores. American Stores noted that its previously announced plan to create a coast-to-coast drug chain under the Osco name continues to move ahead ("The Pink Sheet" May 20, 1985, p. 11). "All of the Skaggs Drug stores have been renamed as Osco, and the majority of the management and record systems have been consolidated at Osco corporate offices in Oak Brook, Illinois." According to the annual report, the final phase of the consolidation, expected to be completed by June, consists of merging Sav-on Drug into Osco. American Stores said that at the end of 1985 its Osco subsidiary operated 483 Osco stores in 29 states, plus 171 Sav-on Drug stores in California, for a total of 654 stores in 30 states "from Maine to California."
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.